Daxibotulinumtoxina-Lanm Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50U, 100U
Reference Brands: Daxxify(USA)
Category:
Derma Drugs
DaxibotulinumtoxinA-lanm is a neuromodulator derived from botulinum toxin type A, designed for injection to temporarily reduce muscle activity. It is approved for the improvement of moderate to severe glabellar (frown) lines in adults, and for the treatment of cervical dystonia in adult patients. Its unique peptide-stabilized formulation allows for longer duration of effect compared to traditional neuromodulators—clinical trials show effect lasting ~6 months and in some up to 9 months.
DaxibotulinumtoxinA-lanm is available in Injection
and strengths such as 50U, 100U.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, DaxibotulinumtoxinA-lanm is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
DaxibotulinumtoxinA-lanm can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
DaxibotulinumtoxinA-lanm is an advanced botulinum toxin type A formulation designed for aesthetic applications requiring prolonged neuromuscular blockade. Marketed as Daxxify by Revance Therapeutics, it is specifically approved for the treatment of moderate to severe glabellar lines (frown lines) in adults. Derived from Clostridium botulinum, this neurotoxin works by inhibiting the release of acetylcholine at the neuromuscular junction, resulting in temporary muscle relaxation and visible reduction in dynamic facial wrinkles.
What differentiates DaxibotulinumtoxinA-lanm from conventional botulinum toxin products is its unique formulation. It contains a highly purified 150-kDa botulinum toxin along with a proprietary stabilizing peptide (RTP004), eliminating the need for human serum albumin. This innovation contributes to its extended duration of action. Clinical studies have demonstrated a median effect duration of approximately 6 months, with some patients experiencing results lasting up to 9 months, significantly reducing the frequency of repeat treatments.
With its long-lasting efficacy, consistent performance, and favorable safety profile, DaxibotulinumtoxinA-lanm represents a next-generation neuromodulator, offering enhanced convenience and improved patient satisfaction in aesthetic practice.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing